Nitin Jain, M.D [slides]-CD7 CAR-T and LCK Inhibition Strategies

In his presentation, Dr. Nitin Jain, MD, delved into the challenges posed by relapsed/refractory T-cell acute lymphoblastic leukemia (TLL) and the pressing need for more effective therapies.


Nitin Jain, M.D., is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA. 

Nitin Jain, MD, discussed relapsed/refractory T-cell acute lymphoblastic leukemia (TLL) and the need for new therapies due to the ineffectiveness of current treatments. They highlighted studies that assessed outcomes in relapsed TLL, demonstrating a median survival of four to six months, indicating the significant unmet medical need. Nitin Jain, MD, also mentioned the criteria for defining early T-cell precursor leukemia (ETPL) based on gene expression and flow cytometry markers. They discussed different approaches for treating ETPL, including CAR T-cell therapy targeting CD7 and inhibiting LCK. Notably, Nitin Jain, MD, presented data from various trials, including ones from China and Singapore, indicating promising clinical activity with these novel therapies.

AML-ALL US - Online content available -
AML-ALL EU - Registration open -
MPN-MDS EU - registration open -

Nitin Jain, MD, focused on the potential of CD7-targeted CAR T-cell therapy, presenting several ongoing studies from different countries. They discussed strategies to overcome challenges associated with fratricide and cytokine release syndrome in CAR T-cell therapy for TLL.